Enanta Pharmaceuticals

Historical price data

Enanta Pharmaceuticals is a clinical-stage biotech focused on discovering and developing oral small-molecule drugs for virology and immunology. The company's foundational achievement was its collaboration with AbbVie that yielded two HCV protease inhibitors, glecaprevir and paritaprevir, which are components of blockbuster combination therapies. Its current strategy pivots on advancing its lead RSV N-protein inhibitor, zelicapavir (EDP-938), and building an immunology pipeline targeting KIT, STAT6, and MRGPRX2 for diseases like chronic spontaneous urticaria. Enanta aims to replicate its HCV success by applying rigorous structure-based drug design to areas of significant unmet medical need.

Structure-based drug design and medicinal chemistry platform focused on discovering novel oral small-molecule inhibitors of viral proteins (e.g., RSV N-protein) and key immune system drivers (KIT, STAT6, MRGPRX2).

In RSV, zelicapavir competes with both preventative vaccines/mAbs and other oral therapeutics in development, requiring clear efficacy differentiation. In immunology, Enanta's oral KIT/STAT6 inhibitors must demonstrate comparable efficacy to established injectable biologics from large pharma to capture market share in crowded type 2 inflammation markets.